Ibrutinib combined with rituximab and high-dose methotrexate in newly diagnosed primary CNS diffuse large B-cell lymphoma: a pilot study with long-term follow-up
In this small pilot cohort, IRM showed promising activity and tolerability as first-line therapy for PCNS DLBCL. These descriptive findings warrant confirmation in larger prospective trials (#ChiCTR1900027811).
Authors
- Tianbin Song (ORCID: https://orcid.org/0000-0002-9646-6539)
- Xiaoli Chang (ORCID: https://orcid.org/0000-0001-5513-5111)
- Dongmei Zou (ORCID: https://orcid.org/0000-0001-6877-2566)
- Wanling Sun (ORCID: https://orcid.org/0000-0001-9429-3024)
- Chunxue Wu
- Yueshan Piao (ORCID: https://orcid.org/0000-0001-6081-1129)
- Wuhan Hui (ORCID: https://orcid.org/0000-0003-2881-1211)
- Yaming Wang (ORCID: https://orcid.org/0000-0001-9621-0261)
- Yongzhi Shan (ORCID: https://orcid.org/0000-0001-5510-1026)
- Li Su (ORCID: https://orcid.org/0000-0002-6347-3986)
- Dandan Wang (ORCID: https://orcid.org/0000-0001-6334-6330)
- Lianghong Teng (ORCID: https://orcid.org/0000-0003-2997-9470)
- Geng Xu (ORCID: https://orcid.org/0000-0002-4597-8729)
- Yixian Guo (ORCID: https://orcid.org/0000-0002-3915-6403)
- Yukui Wei
- Zhilian Zhao
- Hong Zhao
- Qiang Ma (ORCID: https://orcid.org/0000-0002-6096-9396)
Institutions
- Capital Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-02
- DOI
- https://doi.org/10.3389/fonc.2025.1669385
- Citations
- 1
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.39